γδ T cells in cancer
The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Abstract
With the promise of T cell-based therapy for cancer finally becoming reality, this Review focuses on the less-studied γδ T cell lineage and its diverse responses to tumours. γδ T cells have well-established protective roles in cancer, largely on the basis of their potent cytotoxicity and interferon-γ production. Besides this, recent studies have revealed a series of tumour-promoting functions that are linked to interleukin-17-producing γδ T cells. Here, we integrate the current knowledge from both human and mouse studies to highlight the potential of γδ T cell modulation to improve cancer immunotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“γδ T cells can have either protective roles or tumor-promoting functions in cancer; tumor-promoting activities of γδ T cells have been ascribed to distinct mechanisms in different types of cancers (Daley et al., 2016; Silva-Santos et al., 2015).”
From Commensal Microbiota Promote Lung Cancer Development via γδ T Cells (2019) · cites this paper as Silva-Santos et al., 2015
Citations
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
The prognostic landscape of genes and infiltrating immune cells across human cancers
Gentles, A. J., Newman, A. M., Liu, C. L., Bratman, S. V., Feng, W., Kim, D., Nair, V. S., Xu, Y., Khuong, A., Hoang, C. D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3909 · Cited by 3,118
Inflammation-induced cancer: Crosstalk between tumours, immune cells and microorganisms
Elinav, E., Nowarski, R., Thaiss, C. A., Hu, B., Jin, C., & Flavell, R. A. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3611 · Cited by 2,000
IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis
Coffelt, S. B., Kersten, K., Doornebal, C. W., Weiden, J., Vrijland, K., Hau, C.-S., Verstegen, N. J. M., Ciampricotti, M., Hawinkels, L. J. A. C., Jonkers, J., et al. (2015) · Nature · doi:10.1038/nature14282 · Cited by 1,703
Mittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.004 · Cited by 1,471
Immune adaptations that maintain homeostasis with the intestinal microbiota
Hooper, L. V., & Macpherson, A. J. (2010) · Nature Reviews Immunology · doi:10.1038/nri2710 · Cited by 1,454
Six-of-the-best: unique contributions of γδ T cells to immunology
Vantourout, P., & Hayday, A. (2013) · Nature Reviews Immunology · doi:10.1038/nri3384 · Cited by 1,232
Broad tumor-associated expression and recognition by tumor-derived γδ T cells of MICA and MICB
Groh, V., Rhinehart, R., Secrist, H., Bauer, S., Grabstein, K. H., & Spies, T. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6879 · Cited by 1,028
Research works printed but not linked: 1
- Gu, S., Nawrocka, W. & Adams, E. J. Sensing of pyrophosphate metabolites by Vγ9Vδ2 T cells. Front. Immunol. 5, 688 (2014).
Cited by
Items 101–200 of 593
Wistuba‐Hamprecht, K., Martens, A., Haehnel, K., Foppen, M. G., Yuan, J. D., Postow, M. A., Wong, P., Romano, E., Khammari, A., Dréno, B., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.06.001 · Cited by 82
Mevalonate Metabolism in Immuno-Oncology
Gruenbacher, G., & Thurnher, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01714 · Cited by 78
Xu, C., Sui, S., Shang, Y., Yu, Z., Han, J., Zhang, G., Ntim, M., Hu, M., Gong, P., Chen, H., et al. (2020) · Journal of Advanced Research · doi:10.1016/j.jare.2020.03.009 · Cited by 102
Cytotoxic lymphocytes and atherosclerosis: significance, mechanisms and therapeutic challenges
Kyaw, T. S., Peter, K., Li, Y., Tipping, P. G., Toh, B., & Bobik, A. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13845 · Cited by 78
“They are highly effective at killing stressed and tumour cells and produce large amounts of proinflammatory cytokines (Silva-Santos et al., 2015).”
BackgroundLi, X., Lu, H., Gu, Y., Zhang, X., Zhang, G., Shi, T., & Chen, W. (2019) · Experimental Cell Research · doi:10.1016/j.yexcr.2019.111719 · Cited by 77
Dissecting the complexity of γδ T-cell subsets in skin homeostasis, inflammation, and malignancy
Castillo‐González, R., Cibrián, D., & Sánchez‐Madrid, F. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.11.023 · Cited by 79
Harly, C., Joyce, S. P., Domblides, C., Bachelet, T., Pitard, V., Mannat, C., Pappalardo, A., Couzi, L., Netzer, S., Massara, L., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.aba9010 · Cited by 72
“Human T cells are found in tumors and infected tissues, and their expansion in blood correlates with better clinical outcomes in some studies (2).”
BackgroundNormality sensing licenses local T cells for innate-like tissue surveillance
McKenzie, D. R., Hart, R., Bah, N. K., Ushakov, D. S., Muñoz‐Ruiz, M., Feederle, R., & Hayday, A. (2022) · Nature Immunology · doi:10.1038/s41590-021-01124-8 · Cited by 74
Gammadelta T Cells in Crohn’s Disease: A New Player in the Disease Pathogenesis?
Catalán‐Serra, I., Sandvik, A. K., Bruland, T., & Andreu‐Ballester, J. C. (2017) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjx039 · Cited by 75
Li, L., Lu, S., Liang, X., Cao, B., Wang, S., Jiang, J. D., Luo, H., He, S., Lang, J., & Zhu, G. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.11.009 · Cited by 73
Ang, W. X., Ng, Y. Y., Xiao, L., Chen, C., Li, Z., Chi, Z., Tay, J. C.-K., Tan, W. K., Zeng, J., Toh, H. C., et al. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.04.013 · Cited by 73
Memory γδ T Cells–Newly Appreciated Protagonists in Infection and Immunity
Lalor, S. J., & McLoughlin, R. M. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.07.006 · Cited by 76
Rossi, C., Gravelle, P., Decaup, E., Bordenave, J., Poupot, M., Tosolini, M., Franchini, D., Laurent, C., Morin, R., Lagarde, J., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1554175 · Cited by 76
Exosomes Derived from Immune Cells: The New Role of Tumor Immune Microenvironment and Tumor Therapy
Wang, S., & Shi, Y. X. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s388604 · Cited by 73
“Besides, γδ T cells can also activate B cells, DC cells, αβ T cells, NK cells in various ways (eg, act as antigen presenting cells for activation αβ T cells, or NK mediated anti-tumor cytotoxicity induced by costimulatory pathway), so as to achieve indirect killing of tumor.(44,45) Recent studies have shown that γδ T…”
BackgroundTao, Y., Xing, S., Zuo, S., Bao, P., Jin, Y., Li, Y., Li, M., Wu, Y., Chen, S., Wang, X., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101281 · Cited by 76
Fonseca, S., Pereira, V., Lau, C., Teixeira, M. D. A., Antunes, M. B., & Lima, M. (2020) · Cells · doi:10.3390/cells9030729 · Cited by 75
Preillon, J., Cuende, J., Rabolli, V., Garnero, L., Mercier, M., Wald, N., Pappalardo, A., Denies, S., Jamart, D., Michaux, A.-C., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0464 · Cited by 76
“While such activity had been observed in T cells and NK cells, to our knowledge, this is the first demonstration that TIGIT can mediate suppressive activity on T cells and could be involved in TME-induced suppression known to induce deficient T cell functionality or polarization toward Treg phenotype (32,33).”
BackgroundImmune-Mediated Repair: A Matter of Plasticity
Laurent, P., Jolivel, V., Manicki, P., Chiu, L., Contin‐Bordes, C., Truchetet, M., & Pradeu, T. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00454 · Cited by 73
The emerging role of γδ T cells in cancer immunotherapy
Nussbaumer, O., & Koslowski, M. (2019) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2019.06.002 · Cited by 70
Synergistic targeting of breast cancer stem‐like cells by human γδ T cells and CD8+ T cells
Chen, H., Joalland, N., Bridgeman, J. S., Alchami, F., Jarry, U., Khan, M. W. A., Piggott, L., Shanneik, Y., Li, J., Herold, M. J., et al. (2017) · Immunology and Cell Biology · doi:10.1038/icb.2017.21 · Cited by 66
de Witte, M. A., Sarhan, D., Davis, Z., Felices, M., Vallera, D. A., Hinderlie, P., Curtsinger, J., Cooley, S., Wagner, J. E., Kuball, J. H. E., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.02.023 · Cited by 66
Chae, Y. K., Anker, J. F., Bais, P., Namburi, S., Giles, F. J., & Chuang, J. H. (2017) · Oncotarget · doi:10.18632/oncotarget.23742 · Cited by 67
Xiao, L., Chen, C., Li, Z., Zhu, S., Tay, J. C., Zhang, X., Zha, S., Zeng, J., Tan, W. K., Liu, C. X., et al. (2018) · Cytotherapy · doi:10.1016/j.jcyt.2017.12.014 · Cited by 65
Chen, H., Eling, N., Martinez‐Jimenez, C. P., O’Brien, L. M., Carbonaro, V., Marioni, J. C., Odom, D. T., & de la Roche, M. (2019) · EMBO Reports · doi:10.15252/embr.201847379 · Cited by 67
Arruda, L. C. M., Gaballa, A., & Uhlin, M. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000682 · Cited by 66
Chen, H., Alves, M. B. R., & Belleannée, C. (2021) · Human Reproduction Update · doi:10.1093/humupd/dmab029 · Cited by 68
Hede, D. V., Polese, B., Humblet, C., Wilharm, A., Renoux, V., Dortu, E., de Leval, L., Delvenne, P., Desmet, C. J., Bureau, F., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712883114 · Cited by 69
“Tumor cell recognition and associated γδ T-cell activation have been attributed to engagement of the TCR and/or natural killer receptors (NKRs), mostly NKG2D (3).”
BackgroundInfluentialThe role of gamma delta T lymphocytes in breast cancer: a review
Morrow, E. S., Roseweir, A. K., & Edwards, J. (2018) · Translational research · doi:10.1016/j.trsl.2018.08.005 · Cited by 62
Unique T-Cell Populations Define Immune-Inflamed Hepatocellular Carcinoma
Blasi, D. D., Boldanova, T., Mori, L., Terracciano, L., Heim, M. H., & Libero, G. D. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2019.08.004 · Cited by 65
“Their antitumor activity recently has been debated.(50,51) In HCC, we found an enrichment of activated TCR gd cells expressing CD38, CD69, and CD103 markers.”
BackgroundXu, X. J., Li, J., Zou, J., Feng, X., Zhang, C., Zheng, R., Duanmu, W., Saha-Mandal, A., Ming, Z., & Wang, E. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.9292 · Cited by 67
Beyond CAR T Cells: Other Cell-Based Immunotherapeutic Strategies Against Cancer
Patel, S., Burga, R. A., Powell, A. B., Chorvinsky, E. A., Hoq, N., McCormack, S., Pelt, S. N. V., Hanley, P. J., & Cruz, C. C. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00196 · Cited by 62
Bone sarcomas in the immunotherapy era
Heymann, M., Schiavone, K., & Heymann, D. (2020) · British Journal of Pharmacology · doi:10.1111/bph.14999 · Cited by 63
“…Ye, 2012; Liu et al., 2015; Muraro, Mereuta, Carraro, Madon, & Fagioli, 2007; Wang, Li, et al., 2018). γδ T-lymphocyte activation contributes to tumour cell recognition through the engagement of T cell receptor (TCR) and/or natural killer (NK) cell receptors, including (Silva-Santos et al., 2015).”
Background3D Cancer Models: Depicting Cellular Crosstalk within the Tumour Microenvironment
Franchi-Mendes, T., Eduardo, R., Domenici, G., & Brito, C. (2021) · Cancers · doi:10.3390/cancers13184610 · Cited by 68
Bruni, E., Cimino, M. M., Donadon, M., Carriero, R., Terzoli, S., Piazza, R., Ravens, S., Prinz, I., Cazzetta, V., Marzano, P., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004579 · Cited by 57
Guo, X.-Z. J., Dash, P., Calverley, M., Tomchuck, S. L., Dallas, M. H., & Thomas, P. G. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2015.54 · Cited by 60
Nanobodies: The Future of Antibody-Based Immune Therapeutics
Bathula, N. V., Bommadevara, H., & Hayes, J. M. (2020) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2020.3941 · Cited by 63
RNA m 6 A demethylase ALKBH5 regulates the development of γδ T cells
Ding, C., Xu, H. Y., Yu, Z., Roulis, M., Qu, R., Zhou, J., Oh, J., Crawford, J. M., Gao, Y., Jackson, R. P., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2203318119 · Cited by 61
Butyrophilin3A proteins and Vγ9Vδ2 T cell activation
Gu, S., Borowska, M. T., Boughter, C. T., & Adams, E. J. (2018) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2018.02.007 · Cited by 62
von Borstel, A., Chevour, P., Arsovski, D., Krol, J. M. M., Howson, L. J., Berry, A. A., Day, C. L., Ogongo, P., Ernst, J. D., Nomicos, E. Y. H., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe7430 · Cited by 56
Salaroglio, I. C., Belisario, D. C., Akman, M., Vecchia, S. L., Godel, M., Anobile, D. P., Ortone, G., Digiovanni, S., Fontana, S., Costamagna, C., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02447-6 · Cited by 56
“These T-cells are a subset with strong killing properties against tumor cells [20] and have been indicated as the immune-infiltrating population with the highest positive prognostic value in lung cancer [21].”
BackgroundWang, Q., Yu, M., & Zhang, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1440830 · Cited by 68
Silva‐Santos, B., & Strid, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00851 · Cited by 56
Self-citationLi, J., Cao, Y., Liu, Y., Lu, Y., Zhang, Z., Wang, X., Bai, H., Zhang, Y., Liu, S., Gao, M., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008355 · Cited by 65
Multifaceted modes of action of the anticancer probiotic Enterococcus hirae
Goubet, A.-G., Wheeler, R., Fluckiger, A., Qu, B., Lemaître, F., Iribarren, K., Mondragón, L., Tidjani Alou, M., Pizzato, E., Durand, S., et al. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-021-00753-8 · Cited by 54
mTOR signaling in immune cells and its implications for cancer immunotherapy
Zeng, H. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.08.038 · Cited by 56
Buus, T. B., Ødum, N., Geisler, C., & Lauritsen, J. P. H. (2017) · Nature Communications · doi:10.1038/s41467-017-01963-w · Cited by 63
Roles of mTORC1 and mTORC2 in controlling γδ T1 and γδ T17 differentiation and function
Yang, Q., Liu, X., Liu, Q., Guan, Z., Luo, J., Cao, G., Cai, R., Li, Z., Xu, Y., Wu, Z., et al. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-0500-9 · Cited by 56
Sant, S. A., Jenkins, M. R., Dash, P., Watson, K. A., Wang, Z., Pizzolla, A., Koutsakos, M., Nguyen, T. H. O., Lappas, M., Crowe, J., et al. (2019) · Clinical & Translational Immunology · doi:10.1002/cti2.1079 · Cited by 58
PLA2G4A promotes right-sided colorectal cancer progression by inducing CD39+γδ Treg polarization
Zhan, Y., Zheng, L., Liu, J., Hu, D., Wang, J., Liu, K., Guo, J., Zhang, T., & Kong, D. (2021) · JCI Insight · doi:10.1172/jci.insight.148028 · Cited by 58
“The antitumor function of γδ T cells is mainly based on IFN-γ production (18), while the protumor function is linked to IL-17 production (19–21).”
A close look at current γδ T-cell immunotherapy
Ma, L., Feng, Y., & Zhou, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1140623 · Cited by 63
Beyond CAR-T Cells: exploring CAR-NK, CAR-M, and CAR-γδ T strategies in solid tumor immunotherapy
Hou, Y., Hu, S., Chong, L., Chen, X., Wang, Y., Li, Y., Fu, Z., Feng, C., Gong, Y., Liu, Z., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1675807 · Cited by 61
1α,25(OH) 2 D 3 reverses exhaustion and enhances antitumor immunity of human cytotoxic T cells
Li, P., Zhu, X., Cao, G., Wu, R., Li, K., Yuan, W., Chen, B., Sun, G., Xia, X., Zhang, H., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003477 · Cited by 59
Allogeneic gamma delta T cells as adoptive cellular therapy for hematologic malignancies
Jhita, N., & Raikar, S. S. (2022) · Exploration of Immunology · doi:10.37349/ei.2022.00054 · Cited by 56
Acker, H. H. V., Anguille, S., Reu, H. D., Berneman, Z. N., Smits, E., & Tendeloo, V. F. V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00658 · Cited by 54
Bruni, E., Cazzetta, V., Donadon, M., Cimino, M., Torzilli, G., Spata, G., Leonardi, G., Dieli, F., Mikulak, J., & Mavilio, D. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0825-4 · Cited by 54
Yao, T., Shooshtari, P., & Haeryfar, S. M. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01691 · Cited by 56
Jarry, U., Chauvin, C., Joalland, N., Léger, A., Minault, S., Robard, M., Bonneville, M., Oliver, L., Vallette, F. M., Vié, H., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1168554 · Cited by 51
To explore immune synergistic function of Quercetin in inhibiting breast cancer cells
Qiu, D., Yan, X., Xiao, X., Zhang, G., Wang, Y., Cao, J., Ma, R., Hong, S. K., & Ma, M. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02345-5 · Cited by 51
Deep characterization of human γδ T cell subsets defines shared and lineage-specific traits
Sanz, M., Mann, B. T., Ryan, P. L., Bosque, A., Pennington, D. J., Hackstein, H., & Soriano-Sarabia, N. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1148988 · Cited by 59
The epididymal immune balance: a key to preserving male fertility
Drevet, J. R., Guiton, R., Voisin, A., & Saez, F. (2019) · Asian Journal of Andrology · doi:10.4103/aja.aja_11_19 · Cited by 49
Engineering γδT cells limits tonic signaling associated with chimeric antigen receptors
Fisher, J., Sharma, R., Don, D. W., Barisa, M., Hurtado, M. O., Abramowski, P., Porter, L., Day, W., Borea, R., Inglott, S., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aax1872 · Cited by 50
“Engagement of DAP10 promotes PI3K activation (35, 39) and SLP-76 phosphorylation (37).”
ABCA1/ABCB1 Ratio Determines Chemo- and Immune-Sensitivity in Human Osteosarcoma
Belisario, D. C., Akman, M., Godel, M., Campani, V., Patrizio, M. P., Scotti, L., Hattinger, C. M., Rosa, G. D., Donadelli, M., Serra, M., et al. (2020) · Cells · doi:10.3390/cells9030647 · Cited by 53
“Since mice have di ff erent V γ V δ T-cell sets than humans [11], to verify whether NZ could reverse chemo-immune-resistance in preclinical models of osteosarcoma, we used Hu-CD34 + mice, characterized by functional V γ 9 δ 2 T-lymphocytes [30].”
Du, Y., Peng, Q., Cheng, D., Pan, T. S., Sun, W., Wang, H., Ma, X., He, R.-R., Zhang, H., Cui, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27936-8 · Cited by 56
Aging unconventionally: γδ T cells, iNKT cells, and MAIT cells in aging
Kurioka, A., & Klenerman, P. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101816 · Cited by 51
“In vitro studies suggest V δ 1 + T cells have higher anti-tumour cytotoxicity A. Kurioka and P. Klenerman compared to their V δ 2 + counterparts [287,307 – 309].”
BackgroundRodrigues, N. V., Correia, D. V., Mensurado, S., Pereira, S. N., deBarros, A., Kyle‐Cezar, F., Tutt, A. N. J., Hayday, A., Norell, H., Silva‐Santos, B., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0327 · Cited by 48
Self-citationKakimi, K., Matsushita, H., Masuzawa, K., Karasaki, T., Kobayashi, Y., Nagaoka, K., Hosoi, A., Ikemura, S., Kitano, K., Kawada, I., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001185 · Cited by 55
Wei, W., Li, J., Shen, X., Lyu, J., Yan, C., Tang, B., Ma, W., Xie, H., Жао, Л., Cheng, L., et al. (2022) · mSystems · doi:10.1128/msystems.00469-22 · Cited by 47
NKG2D Controls Natural Reactivity of Vγ9Vδ2 T Lymphocytes against Mesenchymal Glioblastoma Cells
Chauvin, C., Joalland, N., Perroteau, J., Jarry, U., Lafrance, L., Willem, C., Retière, C., Oliver, L., Gratas, C., Gautreau‐Rolland, L., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0375 · Cited by 50
Tian, H., Xing, J., Tang, X., Chi, H., Sheng, X., & Zhan, W. (2022) · Marine Life Science & Technology · doi:10.1007/s42995-022-00136-z · Cited by 52
“Conventional αβ T cells are the more plentiful T cell type (90–95%), circulating in lymphoid organs and blood, and can be classified as CD4+ and CD8+ T cells depending on the surface glycoproteins (Hayday 2000; Prinz et al. 2013; Silva-Santos et al. 2015).”
BackgroundThe intestinal γδ T cells: functions in the gut and in the distant organs
Li, G., Xia, J., Zeng, W., Luo, W., Liu, L., Zeng, X., & Cao, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1206299 · Cited by 52
“Frontiers in Immunology 07 NKG2D (natural killer group 2D) (135, 136), and DNAX accessory molecule-1 (DNAM-1), leukocyte function-associated antigen-1 and co-stimulatory receptor CD27 are involved in the cytotoxicity of gd T cells (137).”
BackgroundA population of proinflammatory T cells coexpresses αβ and γδ T cell receptors in mice and humans
Edwards, S. C., Sutton, C. E., Ladell, K., Grant, E. J., McLaren, J. E., Roche, F., Dash, P., Apiwattanakul, N., Awad, W., Miners, K. L., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20190834 · Cited by 49
“γδ T cells are required for optimal innate and adaptive immune responses to infection and tumors (Murphy et al., 2014; Rei et al., 2014; Silva-Santos et al., 2015).”
BackgroundSelf-citationγδ T Cells Provide Protective Function in Highly Pathogenic Avian H5N1 Influenza A Virus Infection
Dong, P., Ju, X., Yan, Y., Zhang, S., Cai, M., Wang, H., Chen, H., Hu, Y., Cui, L., Zhang, J., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02812 · Cited by 45
CARs and beyond: tailoring macrophage-based cell therapeutics to combat solid malignancies
Abdin, S. M., Paasch, D., Morgan, M. A., & Lachmann, N. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002741 · Cited by 49
High-throughput analysis of the human thymic Vδ1+ T cell receptor repertoire
Lorenzo, B. D., Ravens, S., & Silva‐Santos, B. (2019) · Scientific Data · doi:10.1038/s41597-019-0118-2 · Cited by 44
Self-citationA very long-acting IL-15: implications for the immunotherapy of cancer
Hangasky, J. A., Chen, W., Dubois, S. P., Daenthanasanmak, A., Müller, J. R., Reid, R. R., Waldmann, T. A., & Santi, D. V. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004104 · Cited by 43
Metabolites and Immune Response in Tumor Microenvironments
Cortellino, S., & Longo, V. D. (2023) · Cancers · doi:10.3390/cancers15153898 · Cited by 45
Anti-PD-1 antibody armored γδ T cells enhance anti-tumor efficacy in ovarian cancer
Wang, Y., Han, J., Wang, D., Cai, M., Xu, Y., Hu, Y., Chen, H., He, W., & Zhang, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01646-7 · Cited by 43
Wang, X., & Tian, Z. (2018) · Frontiers of Medicine · doi:10.1007/s11684-017-0584-x · Cited by 44
γδ T Cells: Crosstalk Between Microbiota, Chronic Inflammation, and Colorectal Cancer
Yang, Y., Xu, C., Wu, D., Wang, Z., Wu, P., Li, L., Huang, J., & Qiu, F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01483 · Cited by 48
Immune evasion by TGFβ-induced miR-183 repression of MICA/B expression in human lung tumor cells
Trinh, T. L., Kandell, W. M., Donatelli, S. S., Tu, N., Tejera, M. M., Gilvary, D. L., Eksioglu, E. A., Burnette, A., Adams, W. A., Liu, J., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1557372 · Cited by 42
Burnham, R. E., Zoine, J. T., Story, J. Y., Garimalla, S., Gibson, G. C., Rae, A. J., Williams, E., Bixby, L. M., Archer, D. R., Doering, C. B., et al. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.588453 · Cited by 43
Li, Z., Yang, Q., Tang, X., Chen, Y., Wang, S., Qi, X., Zhang, Y., Liu, Z., Luo, J., Liu, H., et al. (2021) · 中国科学通报:英文版 · doi:10.1016/j.scib.2021.11.013 · Cited by 45
Engineering stem cells for cancer immunotherapy
Li, Y.-R., Zhou, Y., Kramer, A. B., & Yang, L. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.08.004 · Cited by 44
Kouakanou, L., Peters, C., Sun, Q., Floess, S., Bhat, J., Huehn, J., & Kabelitz, D. (2020) · Scientific Reports · doi:10.1038/s41598-020-63572-w · Cited by 42
A Palette of Cytokines to Measure Anti-Tumor Efficacy of T Cell-Based Therapeutics
Ramesh, P., Shivde, R. S., Jaishankar, D., Saleiro, D., & Poole, I. C. L. (2021) · Cancers · doi:10.3390/cancers13040821 · Cited by 45
“CD107a (also known as LAMP-1) is not a cytokine, but serves as a substitute marker of cytotoxic activity expressed by natural killer (NK), γδ T cells, and cytotoxic T cells, briefly found on the cell surface upon degranulation [23,24].”
BackgroundThe Diverse Roles of γδ T Cells in Cancer: From Rapid Immunity to Aggressive Lymphoma
Schönefeldt, S., Wais, T., Herling, M., Mustjoki, S. M., Bekiaris, V., Moriggl, R., & Neubauer, H. A. (2021) · Cancers · doi:10.3390/cancers13246212 · Cited by 44
Bongiovanni, A., Foca, F., Menis, J., Stucci, S. L., Artioli, F., Guadalupi, V., Forcignanò, R., Fantini, M., Recine, F., Mercatali, L., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.697298 · Cited by 43
Old and New Players of Inflammation and Their Relationship With Cancer Development
Chavez-Dominguez, R., Perez-Medina, M., Aguilar‐Cázares, D., Galicia-Velasco, M., Meneses-Flores, M., Islas-Vázquez, L., Camarena, Á., & López-González, J. S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.722999 · Cited by 43
Schepisi, G., Gianni, C., Palleschi, M., Bleve, S., Casadei, C., Lolli, C., Ridolfi, L., Martinelli, G., & Giorgi, U. D. (2023) · Cancers · doi:10.3390/cancers15051597 · Cited by 43
TRAIL-Receptor 4 Modulates γδ T Cell-Cytotoxicity Toward Cancer Cells
Tawfik, D., Groth, C., Gundlach, J.-P., Peipp, M., Kabelitz, D., Becker, T., Oberg, H., Trauzold, A., & Wesch, D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02044 · Cited by 43
Mascolo, D. D., Varesano, S., Benelli, R., Mollica, H., Salis, A., Zocchi, M. R., Decuzzi, P., & Poggi, A. D. (2019) · Cancers · doi:10.3390/cancers12010104 · Cited by 40
“Regrettably, murine cancer models present several limitations, considering that the two major γδ T cell subsets do not have orthologues in mice [54,55], and that even syngeneic mice would not be adequate as the response to N-BPs of γδ T cells is different in rodents than in humans [6,8].”
BackgroundBiological and Clinical Aspects of Metastatic Spinal Tumors
Litak, J., Czyżewski, W., Szymoniuk, M., Sakwa, L., Pasierb, B., Litak, J., Hoffman, Z., Kamieniak, P., & Roliński, J. (2022) · Cancers · doi:10.3390/cancers14194599 · Cited by 43
Nitric oxide synthase 2 is involved in the pro-tumorigenic potential of γδ17 T cells in melanoma
Douguet, L., Bod, L., Lengagne, R., Démolis, L. L., Kato, M., Avril, M., & Prévost‐Blondel, A. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1208878 · Cited by 39
Optimized protocols for γδ T cell expansion and lentiviral transduction
Wang, R., Wen, Q., He, W., Yang, J., Zhou, C., Xiong, W., & Ma, L. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.9831 · Cited by 52
“A previous study demonstrated the anti-tumor effects of γδ T cells in various cancer types (39), leading to increasing interest in understanding the potential application of V γ 9 δ 2 T cells in adoptive T cell therapy, particularly in metastatic melanoma.”
Patin, E. C., Soulard, D., Fleury, S., Hassane, M., Dombrowicz, D., Faveeuw, C., Trottein, F., & Paget, C. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1416 · Cited by 39
Functional Plasticity of Gamma Delta T Cells and Breast Tumor Targets in Hypoxia
Siegers, G. M., Dutta, I., Lai, R. L., & Postovit, L.-M. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01367 · Cited by 38
Infiltration of γδ T cells, IL-17+ T cells and FoxP3+ T cells in human breast cancer
Allaoui, R., Hagerling, C., Desmond, E., Warfvinge, C. F., Jirström, K., & Leandersson, K. (2017) · Cancer Biomarkers · doi:10.3233/cbm-170026 · Cited by 42
Heterogeneity of Human γδ T Cells and Their Role in Cancer Immunity
Lee, H. W., Chung, Y. S., & Kim, T. J. (2020) · Immune Network · doi:10.4110/in.2020.20.e5 · Cited by 39
“The ability of γδ T cells to recognize the cellular stress via an MHC-independent mechanism and to potentiate other innate and adaptive immune cells makes them attractive mediators of cancer immunotherapy with potent and broad anti-tumor cytotoxicity (4,7,11,64,65,68,77,82,85,89).”
BackgroundImmunotherapeutic Strategies for Neuroblastoma: Present, Past and Future
Morandi, F., Sabatini, F., Podestà, M., & Airoldi, I. (2021) · Vaccines · doi:10.3390/vaccines9010043 · Cited by 47
Xu, W., Lau, Z. W. X., Fülöp, T., & Larbi, A. (2020) · Cells · doi:10.3390/cells9051181 · Cited by 44
“Vδ1+ cells are implicated in immune responses to viral infections such as CMV, and are able to recognize cancerous cells, as well as react to stress-induced molecules, such as MHC class I-related chains A and B (MICA and MICB) that are expressed on viral infected cells [49,52,75,76].”
Background
Metadata
- Authors
- Silva-Santos, B., Serre, K., & Norell, H.
- Affiliations
- University of Lisbon (PT)
- Corresponding author
- Serre, Karine
- Venue
- Nature reviews. Immunology
- Published
- 2015-10-09
- Volume
- 15
- Issue
- 11
- Pages
- 683-691
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2183777144
- Cited by
- 565
- References
- 95
- Citations by year
- 2026: 30 · 2025: 43 · 2024: 39 · 2023: 60 · 2022: 72 · 2021: 59 · 2020: 63 · 2019: 54 · 2018: 55 · 2017: 56 · 2016: 33
- FWCI
- 4.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- γδ T cells, cancer immunotherapy, tumour immunity, cytotoxicity, interferon-gamma, IL-17, T cell regulation
- MeSH terms
- Animals, Cytotoxicity, Immunologic, Humans, Neoplasms, T-Lymphocytes, Receptors, Antigen, T-Cell, gamma-delta, Interleukin-17, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.